Biodegradable microspheres for protein delivery

被引:662
作者
Sinha, VR [1 ]
Trehan, A [1 ]
机构
[1] Panjab Univ, Univ Inst Pharmaceut Sci, Dept Pharmaceut, Chandigarh 160014, India
关键词
microspheres; delivery systems; protein stability;
D O I
10.1016/S0168-3659(03)00194-9
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In a very short time, since their emergence, the field of controlled delivery of proteins has grown immensely. Because of their relatively large size, they have low transdermal bioavailabilities. Oral bioavailability is generally poor since they are poorly absorbed and easily degraded by proteolytic enzymes in the gastrointestinal tract. Ocular and nasal delivery is also unfavorable due to degradation by enzymes present in eye tissues and nasal mucosa. Thus parenteral delivery is currently most demanding and suitable for delivery of such molecules. In systemic delivery of proteins, biodegradable microspheres as parenteral depot formulation occupy an important place because of several aspects like protection of sensitive proteins from degradation, prolonged or modified release, pulsatile release patterns. The main objective in developing controlled release protein injectables is avoidance of regular invasive doses which in turn provide patient compliance, comfort as well as control over blood levels. This review presents the outstanding contributions in field of biodegradable microspheres as protein delivery systems, their methods of preparation, drug release, stability, interaction with immune system and regulatory considerations. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:261 / 280
页数:20
相关论文
共 113 条
[1]   PLGA microspheres containing plasmid DNA: Preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization [J].
Ando, S ;
Putnam, D ;
Pack, DW ;
Langer, R .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) :126-130
[2]  
[Anonymous], CONTROLLED NOVEL DRU
[3]   PROTEIN-SOLVENT INTERACTIONS IN PHARMACEUTICAL FORMULATIONS [J].
ARAKAWA, T ;
KITA, Y ;
CARPENTER, JF .
PHARMACEUTICAL RESEARCH, 1991, 8 (03) :285-291
[4]  
AUTIAN J, 1983, FUNDAMENTAL ASPECTS, P63
[5]   SYSTEMIC DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS [J].
BANGA, AK ;
CHIEN, YW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1988, 48 (1-3) :15-50
[6]   Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics [J].
Bittner, B ;
Morlock, M ;
Koll, H ;
Winter, G ;
Kissel, T .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 45 (03) :295-305
[7]   In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres [J].
Blanco-Príeto, MJ ;
Besseghir, K ;
Zerbe, O ;
Andris, D ;
Orsolini, P ;
Heimgartner, F ;
Merkle, HP ;
Gander, B .
JOURNAL OF CONTROLLED RELEASE, 2000, 67 (01) :19-28
[8]   On technological and immunological benefits of multivalent single-injection microsphere vaccines [J].
Boehm, G ;
Peyre, M ;
Sesardic, D ;
Huskisson, RJ ;
Mawas, F ;
Douglas, A ;
Xing, D ;
Merkle, HP ;
Gander, B ;
Johansen, P .
PHARMACEUTICAL RESEARCH, 2002, 19 (09) :1330-1336
[9]  
BRANNONPEPPAS L, 1994, 21 INT M CONTR REL S, P27
[10]  
BRONAUGH RL, 1982, SAFETY EFFICACY TOPI, P51